Search Results - "RYMER, JENNIFER A."

Use of Open Access Platforms for Clinical Trial Data by Navar, Ann Marie, Pencina, Michael J, Rymer, Jennifer A, Louzao, Darcy M, Peterson, Eric D

Get full text

Caution About Overinterpretation of Symptom Indexes in Reflux Monitoring for Refractory Gastroesophageal Reflux Disease by Slaughter, James C, Goutte, Marion, Rymer, Jennifer A, Oranu, Amanke C, Schneider, Jonathan A, Garrett, C. Gaelyn, Hagaman, David, Vaezi, Michael F

“…Background & Aims Symptom index (SI) and symptom association probability (SAP) are indexes used to analyze data collected from ambulatory pH and/or impedance…”
Get full text

Difference in Medication Adherence Between Patients Prescribed a 30-Day Versus 90-Day Supply After Acute Myocardial Infarction by Rymer, Jennifer A, Fonseca, Eileen, Bhandary, Durgesh D, Kumar, Deepa, Khan, Naeem D, Wang, Tracy Y

“…Background Evidence-based medication adherence rates after a myocardial infarction are low. We hypothesized that 90-day prescriptions are underused and may…”
Get full text

Invasive Versus Conservative Strategy in Older Adults ≥75 Years of Age With Non–ST‐segment–Elevation Acute Coronary Syndrome: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials by Rout, Amit, Moumneh, Mohamad B., Kalra, Kriti, Singh, Sahib, Garg, Aakash, Kunadian, Vijay, Biscaglia, Simone, Alkhouli, Mohamad A., Rymer, Jennifer A., Batchelor, Wayne B., Nanna, Michael G., Damluji, Abdulla A.

“…Background Older adults with non–ST‐segment–elevation acute coronary syndrome are less likely to undergo an invasive strategy compared with younger patients…”
Get full text

Differences in Preferences Between Clinicians and Patients for the Use and Dosing of Direct Oral Anticoagulants for Atrial Fibrillation by Rymer, Jennifer A, Webb, Laura, McCall, Debbe, Hills, Mellanie T, Wang, Tracy Y

“…Background Direct oral anticoagulants (DOACs) are effective in reducing the stroke risk for patients with nonvalvular atrial fibrillation if prescribed at the…”
Get full text

Challenge in Predicting Persistence to P2Y12 Inhibitors: A Perspective From the ARTEMIS Trial by Rymer, Jennifer A, Wegermann, Zachary K, Kaltenbach, Lisa A, Webb, Laura E, Peterson, Eric D, Wang, Tracy Y

“…Background Premature discontinuation of P2Y12 inhibitor therapy has been associated with adverse cardiac events, which might be preventable by improving…”
Get full text

Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke by Navar-Boggan, Ann Marie, MD, PhD, Rymer, Jennifer A., MD, MBA, Piccini, Jonathan P., MD, MHS, Shatila, Wassim, MD, Ring, Lauren, BS, Stafford, Judith A., MS, Al-Khatib, Sana M., MD, MHS, Peterson, Eric D., MD, MPH

“…Background There is no universally accepted algorithm for identifying atrial fibrillation (AF) patients and stroke risk using electronic data for use in…”
Get full text

Readmissions After Acute Myocardial Infarction: How Often Do Patients Return to the Discharging Hospital? by Rymer, Jennifer A, Chen, Anita Y, Thomas, Laine, Fonarow, Gregg C, Peterson, Eric D, Wang, Tracy Y

“…Background When patients require readmission after a recent myocardial infarction (MI), returning to the discharging (index) hospital may be associated with…”
Get full text

Use of Low-Density Lipoprotein-Lowering Therapies Before and After PCSK9 Inhibitor Initiation by Rymer, Jennifer A, Mues, Katherine E, Monda, Keri L, Bratton, Emily W, Wirtz, Heidi S, Okerson, Ted, Overman, Robert A, Brookhart, M Alan, Muntner, Paul, Wang, Tracy Y

“…Background Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are used to reduce low-density lipoprotein (LDL) cholesterol. PCSK9i use after…”
Get full text

Does the Effectiveness of a Medicine Copay Voucher Vary by Baseline Medication Out‐Of‐Pocket Expenses? Insights From ARTEMIS by Rymer, Jennifer A., Kaltenbach, Lisa A., Peterson, Eric D., Cohen, David J., Fonarow, Gregg C., Choudhry, Niteesh K., Henry, Timothy D., Cannon, Christopher P., Wang, Tracy Y.

“…Background Persistence to P2Y12 inhibitors after myocardial infarction (MI) remains low. Out‐of‐pocket cost is cited as a factor affecting medication…”
Get full text

Safety of Dual-Antiplatelet Therapy After Myocardial Infarction Among Patients With Chronic Kidney Disease by Rymer, Jennifer A, Kaltenbach, Lisa A, Doll, Jacob A, Messenger, John C, Peterson, Eric D, Wang, Tracy Y

“…Background Although recommended in the guidelines, the safety of chronic P2Y inhibitor therapy in patients with chronic kidney disease ( CKD ) after an acute…”
Get full text

Cangrelor Use Patterns and Transition to Oral P2Y12 Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO Registry by Rymer, Jennifer A, Bhatt, Deepak L, Angiolillo, Dominick J, Diaz, Miguel, Garratt, Kirk N, Waksman, Ron, Edwards, Laura, Tasissa, Gudaye, Salahuddin, Khalid, El-Sabae, Hijrah, Dell'Anna, Carmen, Davidson-Ray, Linda, Washam, Jeffrey B, Ohman, E Magnus, Wang, Tracy Y

“…Background In clinical trials, cangrelor has been shown to reduce percutaneous coronary intervention–related ischemic complications without increasing major…”
Get full text

Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in Symptomatic Peripheral Artery Disease) Trial by Rymer, Jennifer A, Mulder, Hillary, Smolderen, Kim G, Hiatt, William R, Conte, Michael S, Berger, Jeffrey S, Norgren, Lars, Mahaffey, Kenneth W, Baumgartner, Iris, Fowkes, F Gerry, Katona, Brian G, Rockhold, Frank, Jones, W Schuyler, Patel, Manesh R

“…Background There are limited data on health status instruments in patients with peripheral artery disease and cardiovascular and limb events. We evaluated the…”
Get full text

Advanced Practice Provider Versus Physician-Only Outpatient Follow-Up After Acute Myocardial Infarction by Rymer, Jennifer A, Chen, Anita Y, Thomas, Laine, Stafford, Judith, Enriquez, Jonathan R, Goyal, Abhinav, Peterson, Eric D, Wang, Tracy Y

“…Background Physician shortages and reimbursement changes have led to greater use of advanced practice providers ( APP s). Prevalence of and outcomes associated…”
Get full text

The Management and Treatment of Cardiogenic Shock: Is Sex Still a Factor? by GILCHRIST, JULIANN, RYMER, JENNIFER A.

Get full text

Health-Related Quality of Life Instruments in Chronic Limb-Threatening Ischemia: Evolution of Defining Quality of Life in a Complex Disease State by Rymer, Jennifer A, Patel, Manesh R

Get full text

Does This Patient With Chest Pain Have Acute Coronary Syndrome?: The Rational Clinical Examination Systematic Review by Fanaroff, Alexander C, Rymer, Jennifer A, Goldstein, Sarah A, Simel, David L, Newby, L. Kristin

“…IMPORTANCE: About 10% of patients with acute chest pain are ultimately diagnosed with acute coronary syndrome (ACS). Early, accurate estimation of the…”
Get full text

Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial by Pokorney, Sean D., Chertow, Glenn M., Al-Khalidi, Hussein R., Gallup, Dianne, Dignacco, Pat, Mussina, Kurt, Bansal, Nisha, Gadegbeku, Crystal A., Garcia, David A., Garonzik, Samira, Lopes, Renato D., Mahaffey, Kenneth W., Matsuda, Kelly, Middleton, John P., Rymer, Jennifer A., Sands, George H., Thadhani, Ravi, Thomas, Kevin L., Washam, Jeffrey B., Winkelmayer, Wolfgang C., Granger, Christopher B.

“…There are no randomized data evaluating the safety or efficacy of apixaban for stroke prevention in patients with end-stage kidney disease on hemodialysis and…”
Get full text

Drug-Coated Balloons With or Without Provisional Bare Metal Stenting in Femoropopliteal Disease: No Metal Left Behind? by Rymer, Jennifer A, Gutierrez, J Antonio

Get full text

Dual Antiplatelet and Anticoagulation Regimens for Women Undergoing Percutaneous Coronary Intervention by Kansal, Aman, Swamy, Pooja, Rymer, Jennifer A.

“…Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention is necessary for preventing stent thrombosis and ensuring long-term cardiovascular…”
Get full text